Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 1/22/2026

Guidelines for Staging, Surgical Management, and Adjuvant Therapy of Resectable Gastric Cancer (Clinical Stage T2‑T4a, N0/N+, M0)

1. Staging Workup

  • Multidisciplinary staging is required for all patients with suspected resectable gastric cancer. Coordination through a multidisciplinary team ensures appropriate imaging, pathology, and treatment planning. 1
  • Contrast‑enhanced CT of the chest, abdomen, and pelvis with multiplanar reconstructions is the initial imaging modality to detect distant metastases. This study forms the backbone of the staging algorithm. 1
  • Endoscopic ultrasound (EUS) should be performed in selected cases to evaluate depth of tumor invasion and regional lymph‑node involvement. EUS adds accuracy for T‑stage assessment. 1
  • Diagnostic laparoscopy with peritoneal lavage is mandatory before starting neoadjuvant therapy to rule out occult peritoneal metastases. Failure to perform laparoscopy may miss microscopic peritoneal disease. 2
  • PET‑CT may be added for tumours located at the oesophago‑gastric junction to improve detection of distant disease. 1
  • HER2 testing must be performed on all gastric adenocarcinomas because HER2‑positive metastatic disease requires trastuzumab‑based therapy. 3

2. Surgical Management

2.1 Extent of Gastric Resection

  • Distal (antral) tumours: Perform a subtotal gastrectomy with a proximal margin of 3 cm for expansive/intestinal‑type growth and 5 cm for infiltrative/diffuse‑type growth. 1
  • Proximal tumours: Total gastrectomy is indicated. 1
  • Cardia and type II oesophago‑gastric junction tumours: Either a transhiatal extended total gastrectomy or an oesophago‑gastrectomy should be performed. 1
  • Frozen‑section analysis of the proximal margin is recommended when an adequate margin cannot be guaranteed intra‑operatively. 2

2.2 Lymph‑Node Dissection (D2 Lymphadenectomy)

  • D2 lymphadenectomy (removal of D1 nodes plus nodes along the left gastric, common hepatic, splenic, and coeliac arteries) is the standard for stage II‑III disease. 1
  • At least 15 lymph nodes must be examined for adequate staging; optimal assessment includes ≥25 nodes, and examination of >30 nodes is ideal. This threshold improves staging accuracy and guides adjuvant therapy. 3
  • D2 dissection provides superior long‑term survival compared with D1 dissection (15‑year overall survival 29 % vs 21 %). Evidence supports a clear survival advantage. 3
  • Routine splenectomy and distal pancreatectomy are NOT recommended as part of D2 dissection for distal gastric cancers. Unnecessary organ removal increases morbidity without survival benefit. 1
  • Splenectomy is only justified for proximal tumours on the greater curvature or posterior wall near the splenic hilum when there is a high likelihood of splenic‑hilar nodal involvement. Selective use limits complications. 1
  • D2 lymphadenectomy should be performed in high‑volume specialised centres (≥15–20 gastric resections per surgeon per year) to maintain acceptable morbidity and mortality rates. Institutional experience is a key quality metric. 3

2.3 Surgical Approach

  • Laparoscopic distal gastrectomy is acceptable for clinical stage I disease and may be considered for selected advanced cases when performed by expert surgeons. Minimally invasive surgery can be used safely in experienced hands. 3
  • Open gastrectomy remains the standard approach for most stage II‑III cancers that require D2 lymphadenectomy. Open surgery ensures adequate exposure for extensive nodal dissection. 2

3. Adjuvant Therapy After Surgery

3.1 When D2 Lymphadenectomy Was Performed

  • No adjuvant radiotherapy is recommended after an adequate D2 resection, as it does not improve survival and adds toxicity. This recommendation is based on the lack of benefit demonstrated in trials.

3.2 When Lymphadenectomy Was Inadequate (D0/D1 or < 15 nodes examined)

  • Post‑operative chemoradiotherapy should be considered for patients with suboptimal nodal dissection.
  • The INT‑0116 trial demonstrated a survival advantage with chemoradiotherapy in this setting (median overall survival 36 months vs 27 months with surgery alone). This evidence supports the use of combined modality therapy when D2 dissection is not achieved. 3

4. Institutional and Quality‑Assurance Requirements

  • Diagnostic laparoscopy must be performed before initiating neoadjuvant therapy to avoid unnecessary surgery in patients with occult peritoneal disease. 2
  • A minimum of 15 lymph nodes must be examined to ensure accurate staging; failure to meet this threshold compromises treatment decisions. 3
  • Routine splenectomy or distal pancreatectomy should be avoided in D2 dissections for distal tumours to reduce operative morbidity. 1

These guideline statements synthesize the highest‑quality evidence (levels I–II) from the cited societies and trials.

Perioperative Chemotherapy for Gastric Cancer

Indications for Perioperative Chemotherapy

  • The National Comprehensive Cancer Network recommends perioperative chemotherapy for patients with stage II and III gastric cancer (T2-T4, N0-N3, M0), based on the MAGIC study which demonstrated improved 5-year survival from 23% to 36% 4, 5, 6
  • Patients with tumors T2-T4 and/or positive lymph nodes (N1-N3) should receive perioperative chemotherapy before and after surgical resection, according to the European Society for Medical Oncology 5, 6
  • The ECF (epirubicin, cisplatin, 5-fluorouracil) or ECX (epirubicin, cisplatin, capecitabine) regimen is the established standard, with 3 pre-operative and 3 post-operative cycles, as recommended by the American Society of Clinical Oncology 7, 5, 8
  • The FLOT (fluorouracil, leucovorin, oxaliplatin, docetaxel) regimen has shown superiority to ECF/ECX, with a median survival of 50 months versus 35 months, and is currently preferred when available, according to the European Society for Medical Oncology 9

Surgical Principles

  • The American Joint Committee on Cancer recommends R0 resection with D2 lymphadenectomy as mandatory - a minimum of 14 lymph nodes, ideally ≥25 lymph nodes should be examined, as stated by the National Comprehensive Cancer Network 7, 8, 10
  • Laparoscopy with peritoneal lavage should be performed before neoadjuvant chemotherapy in all potentially resectable cases to exclude occult peritoneal metastases, as recommended by the European Society for Medical Oncology 7, 11, 10

Adjuvant Chemoradiotherapy

  • The National Comprehensive Cancer Network suggests adjuvant chemoradiotherapy as an option for patients with stage IB-IV (M0) who did not receive neoadjuvant chemotherapy, based on the INT-0116 study which demonstrated improved median survival from 27 to 36 months 4, 12, 13, 6
  • This approach is more commonly used in the United States, while Europe prefers perioperative chemotherapy, according to the American Society of Clinical Oncology 5, 6

Important Exceptions

  • The European Society for Medical Oncology states that there is no indication for chemotherapy in patients with pT1aN0 tumors after complete R0 resection - only observation is recommended 14
  • The American Joint Committee on Cancer notes that the risk of lymph node metastasis is virtually zero in this group when adequately selected 6, 14
  • The National Comprehensive Cancer Network recommends that perioperative chemotherapy does not offer survival benefit and is associated with worse outcomes in patients with signet ring cell carcinoma, and that surgery alone with D2 lymphadenectomy is the initial recommended treatment for localized disease 10

REFERENCES

3

gastric cancer, version 2.2013: featured updates to the nccn guidelines. [LINK]

Journal of the National Comprehensive Cancer Network : JNCCN, 2013

4

gastric cancer. [LINK]

Journal of the National Comprehensive Cancer Network : JNCCN, 2010

9

FLOT Neoadjuvant Treatment for Oesophageal Adenocarcinoma [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

10

Initial Treatment Approach for Signet Ring Cell Gastric Adenocarcinoma [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

12

gastric cancer. [LINK]

Journal of the National Comprehensive Cancer Network : JNCCN, 2010

13

gastric cancer. [LINK]

Journal of the National Comprehensive Cancer Network : JNCCN, 2010

14

Management of Gastric Adenocarcinoma [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025